EGFR and neoplasm: Our data also showed that the combination of bispecific antibodies plus talazoparib, but not a bispecific antibody alone, was particularly effective for suppressing tumour growth compared with monotherapy, combined treatment with cetuximab and talazoparib or individual treatment with bispecific antibodies in PDX models with sensitivity to EGFR blockade.